MGMartin Guevara

Martin Guevara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Guevara has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Planificación Neuroquirúrgica con Software Osirix Neurosurgical planning using osirix software

    by SebastianGaston Jaimovich, Martin Guevara, Sergio Pampin, Roberto Jaimovich, JavierLuis Gardella

    Anatomical individuality is key to reduce surgical trauma and obtain a better outcome. Nowadays, the advances in neuroimaging has allowed us to analyze this anatomical individuality and to plan the surgery. With this objective, we present our experience with the OsiriX software. We present three different applications as example of forty procedures performed. Case 1: Patient with a premotor cortex convexity parasagittal meningioma; Case 2: Patient with a nonfunctioning pituitary macroadenoma operated on 2 years ago in another institution, achieving a partial resection by a transsphenoidal approach; Case 3: Patient with bilateral middle cerebellar peduncles lesions. OsiriX Software was used for surgical planning. Volumetric CT and MRI images were fused and 3D reconstruction images obtained, to analyze anatomical relationships, measure distances, coordinates and trajectories, among other features. OsiriX software is a useful, open-source and free software tool that provides the surgeon with valuable information. It allows to study individual patient's anatomy and plan a surgical approach in a fast, simple, inexpensive and safety way. In Case 1 the software let us analyze the relationship of the tumor with the surrounding structures in order to minimize the approach's morbidity. In Case 2, to understand the unique anatomic characteristics of an already operated patient giving us important information regarding pathways and need for extra bone removal, achieving a complete tumor resection by an endoscopic transnasal approach. In Case 3, allowed us to obtain the stereotactic coordinates and trajectory for a not visualizable CT scan lesion. When expensive neuronavigation systems are not available, OsiriX is an alternative for neurosurgical planning, with the aim of reducing trauma and surgical morbidity.


  • Open Access

    Cavernous sinus tuberculoma mimicking a neoplasm: Case report, literature review, and diagnostic and treatment suggestions for tuberculomas in rare locations

    by Sebastián G Jaimovich, Victor Castillo Thea, Martin Guevara, Javier L Gardella

    Background: Cavernous sinus tuberculomas are extremely rare, but the increasing incidence worldwide of central nervous system (CNS) tuberculosis, mostly due to human immunodeficiency virus and poor sanitary conditions, and the ability of tuberculomas to mimic a brain neoplasm makes cavernous sinus tuberculomas a suspicious pathologic finding in the differential diagnosis of a brain space-occupying lesion. Case Description: We present an immunocompetent patient with no signs of systemic tuberculosis and an isolated right cavernous sinus space-occupying lesion. A skull base approach was performed and tumor resection achieved. The postoperative course was uneventful. Pathologic findings consisted of a tuberculoma and antituberculous treatment was immediately begun with total tumor regression after a 12-month regimen. After reviewing the literature, we propose suggestions to orient the diagnosis and a treatment algorithm for tuberculomas in rare locations. Conclusion: Tuberculomas in rare locations, as the cavernous sinus, are a challenging pathology as they have the ability to mimic a brain neoplasm. Although first line treatment are antituberculous therapy (4 drugs for at least 12 months) and adjuvant steroids, in inconclusive cases, surgical biopsy or excision is recommended for histopathologic confirmation and to reduce the mass effect, always following with antituberculous therapy and adjuvant steroids.